Tactical Therapeutics new drug Carboxyamidotriazole Orotate (CTO) is getting notoriety for its success in treating Brain Cancer Patients who went through a Phase 1 trial at the Memorial Sloan Kettering Cancer Center in New York, NY. December 6, 2022